Navigation Links
Synthetic lethality: A new way to kill cancer cells
Date:2/22/2010

Ovarian and breast cancer treatments being developed that mix a protein inhibitor and traditional anticancer drugs are showing signs of success, according to a new review for Faculty of 1000 Biology Reports.

Susan Bates and Christina Annunziata looked at several recent papers on this form of treatment, which takes advantage of the synthetic lethality of BRCA (breast cancer susceptibility genes) and poly-ADP ribose polymerase (PARP) proteins to attack cancerous cells whilst sparing healthy ones.

BRCA and PARP are two key players in DNA repair and have different but complementary functions in the cell. Loss of the BRCA protein still allows the cell to survive but greatly increases its chances of becoming cancerous through the accumulation of mutations. The loss of both proteins, however, kills the cell in a process called synthetic lethality.

Researchers, by using drugs to block the activity of PARP in cells missing BRCA, such as those found in certain breast and ovarian cancers, can help spare healthy, non-cancerous cells because they have functional BRCA and are not affected by the loss of PARP. Thus, only cancer cells without functional BRCA protein are killed by drugs that inhibit PARP.

Recent clinical trials have shown that cancers caused by mutations that knock out BRCA activity can be controlled by blocking PARP activity with specific drugs. Patients were treated with traditional anticancer drugs alone or in combination with one of two new PARP inhibitors, olaparib or BSI-201.

Bates notes that patients on combination therapy had improved "[disease] progression-free survival, and overall survival" as compared to patients treated with traditional drugs alone.

Bates is optimistic about the promise of combining PARP inhibitors with existing cancer drugs. She says that the results of these clinical trials "have provided proof of principle in achieving synthetic lethality" with PARP-inhibiting drugs and that treatments combining novel PARP inhibitors with traditional chemotherapeutic drugs have the potential to vanquish BRCA-associated breast and ovarian cancers.


'/>"/>

Contact: Steve Pogonowski
press@f1000.com
Faculty of 1000: Biology and Medicine
Source:Eurekalert  

Related biology news :

1. Biotech, nanotech and synthetic biology roles in future food supply explored
2. Synthetic protein mimics structure, function of metalloprotein in nature
3. Synthetic biology offers new opportunities for interdisciplinary collaboration
4. New synthetic molecules trigger immune response to HIV and prostate cancer
5. Sun or shade: Pecan leaves photosynthetic light response evaluated
6. Synthetic cells shed biological insights while delivering battery power
7. Understanding a cells split personality aids synthetic circuits
8. Nanotechnology and synthetic biology: What does the American public think?
9. Synthetic Biology Project receives 2 National Science Foundation grants
10. July 9-10 symposium on synthetic biology
11. Synthetic catalyst mimics natures hydrogen economy
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Synthetic lethality: A new way to kill cancer cells
(Date:1/4/2017)... , Jan. 4, 2017  For the thousands of attendees at this ... leader in connected health and biometric measurement devices and services, will be ... On display in A&D Medical,s special CES Exhibit Suite , ... ongoing expansion of the company,s WellnessConnected product platform.  ... ...
(Date:1/3/2017)... 3, 2017 Onitor, provider of digital health ... Track, an innovative biometric data-driven program designed to aid ... at the 2017 Consumer Electronics Show (CES) in ... the U.S., the World Health Organization (WHO), have identified ... adults who are overweight or obese. WHO also states ...
(Date:12/22/2016)... SuperCom (NASDAQ:   SPCB ... Safety, HealthCare, and Finance sectors announced today that Leaders in Community ... and deploy a community-based supportive services program to reduce recidivism in ... expanding its presence in the state. ... This new program, which is expected to commence ...
Breaking Biology News(10 mins):
(Date:1/20/2017)... 20, 2017 Stock-Callers.com explores the ... influenced the most recent performances of select equities. In ... RGLS ), Abeona Therapeutics Inc. (NASDAQ: ... ), and Sage Therapeutics Inc. (NASDAQ: SAGE ... View Research, global Biotech market size is expected to reach $604.40 billion by ...
(Date:1/19/2017)... Research and Markets has announced the addition of the ... - Global Opportunity Analysis and Industry Forecast, 2014-2022" report to ... ... to reach $15,737 million by 2022 from $6,521 in 2015, growing ... Omic technologies segment accounted for more than half of the ...
(Date:1/19/2017)... Jan 19, 2017 Research and Markets ... has announced the addition of the ... - Forecast to 2025" report to their offering. ... The report provides a detailed analysis on current and future market ... 2025, using estimated market values as the base numbers ...
(Date:1/19/2017)... , Jan. 19, 2017  ArmaGen, Inc., today ... , Ph.D., as chief executive officer, as well ... Dr. Schmidt brings to ArmaGen more than 17 years ... and development of biotherapeutics and pharmaceuticals. ... the diverse experience and skillset necessary to lead ...
Breaking Biology Technology: